Szwajgier D. Anticholinesterase activity of selected phenolic acids and flavonoids: interaction testing in model solutions. Ann Agric Environ Med. 2015; 22(4): 690-694. doi: 10.5604/12321966.1185777 Abstract Introduction. Alzheimer's disease is a progressively developing neurodegenerative disorder of the central nervous system. The only present treatment of this disease is the use of acetyl-and butyrylcholinesterase inhibitors. Previously, the neuroprotection of phenolic acids and flavonoids in the brain has been indicated. Materials and method. This study measured anticholinesterase activities of 9 phenolic acids and 6 flavonoids, singly or in combination. The synergy/antagonism/zero interaction between compounds was evaluated taking into consideration the statistical significance. Ellman's modified spectrophotometric method was used with the simultaneous measurement of the false-positive effect of compounds. Results. The anti-acetylcholinesterase activity of phenolic acids was as follows: homogentisic acid > 4-hydroxyphenylpyruvic acid > nordihydroguaiaretic acid > rosmarinic acid > caffeic acid > gallic acid = chlorogenic acid > homovanillic acid > sinapic acid. p-Hydroxyphenylpyruvic, caffeic, chlorogenic, gentisic, homogentisic, nordihydroguaiaretic and rosmarinic acids in pairs exhibited, in most cases, a lower inhibitory activity (at p>0.05), than the sum of the activities of single compounds. Also, phenolic acids in pairs with flavonoids (cyanidin, delphinidin, kaempferol, myricetin, phloridzin, pelargonidin or quercetin) presented, in most cases, a lower inhibitory activity than could be calculated for both compounds singly (at p>0.05). Only in the case of a few samples was the inhibitory activity of two compounds higher than the sum of inhibitions exerted by the same compounds tested singly (either at p>0.05 or p<0.05). The lack of synergy of pairs of inhibitors suggests one small binding site, making impossible to accommodate both inhibitors adjacent to one another.
INTRODUCTION
The neuroprotection of phenolic acids has been previously repeatedly highlighted, e.g. of ferulic acid in the central nervous system of experimental animals [1] . Ferulic acid, p-coumaric acid, 4-hydroxybenzoic acid and sinapic acid are efficient in vitro acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors [2] . Sinapic acid and ferulic acid participate in the regulation of the acetylcholinesignalling system in experimental animals [3] . Amyloid-β plaque deposition is significantly decreased in brains of mice fed nordihydroguaiaretic (NDGA) and rosmarinic acid (RA). Treatment with RA, curcumin and myricetin causes an increase in the content of soluble β-amyloid [4] .
Previously, flavonoids had been identified as effective antioxidants in the brain [5] . Anthocyanins pelargonidin (PEL), delphinidin (DEL) and cyanidin (CYA), flavones apigenin and luteolin, flavonols quercetin (QUE), kaempferol (KAE) and myricetin (MYR), dihydrochalcone phloridzin (PHL) and prenylated chalcone xanthohumol are the most efficient in vitro inhibitors of AChE and/or BChE in a study testing 24 polyphenols. The lowest inhibitory activity is exerted by flavan-3-ols [6] . Flavonoids inhibit the formation and extension of amyloid-β (1 -40) or (1 -42) fibrils (in decreasing order: MYR = morin = QUE > KAE > (+)-catechin = (-)-epicatechin [7] . Also, flavonoids effectively destabilize preformed β-amyloid fibrils in a dose-dependent manner [7, 8] . MYR decreases the toxicity of β-amyloid fibrils [7] . Genistein and daidzein increases AChE activity in rat neuronal cells PC12 [9] . (-)-Epigallocatechin gallate, hydroxytyrosol, resveratrol and tyrosol exhibit a cytoprotective effect on neuroblastoma IMR-32 and lymphoma U937 cell lines via an increase in the resistance of cellular DNA to oxidative damage [10] . (-)-Epigallocatechin gallate reduces free radical and malondialdehyde content, increases caspase activity after ex vivo pretreatment with β-amyloid, and elevates the percentage survival rate of hippocampal neuronal cells from Sprague-Dawley rat embryos previously incubated with β-amyloid [11] . CYA, KAE, epicatechin, rutin, naringenin, taxifolin and luteolin exert a neuroprotective role towards the primary cells of mouse striatal neurons in the presence of oxidized low-density lipoproteins [12] .
Alzheimer's disease (AD) is a severe disease of the central nervous system involving the loss of cholinergic neurons [13] , an imbalance of the AChE and BChE activity and the deposition of intra-and extracellular β-amyloid in the brain tissue [14] . The present therapeutics are based on the inhibition of AChE and BChE activity in the brain leading to an increase in brain ACh levels. Therefore, the aim of the present work was to compare the anticholinesterase activities of selected phenolic acids singly, and in pairs as well as in combination with selected flavonoids in order to study interactions between these compounds. Inhibition of AChE and BChE. Inhibitory activity was evaluated using a 96-well microplate reader (Tecan Sunrise, Grödig, Austria) based on the method of Ellman et al. [15] with some modifications, as described previously [2] . The absorbance at 405 nm was read after 30 min (AChE) or 15 min (BChE). The false-positive effect was determined according to the method of Rhee et al. [16] , with some modifications as previously described [2] . Blank as well as false-positive samples were run in the case of each analysis presented in this study. The inhibitory activity of phenolic compounds was expressed in μM serine, as previously proposed [2, 17] . Dose-response curves were plotted using eleven solutions of eserine in the range of 11.50 mmol/L -10.90 μmol/L. Each sample was analyzed in eight repeats, unless otherwise stated. Statistical differences were calculated using Tukey's test (STATISTICA 8.0, StatSoft, Kraków, Poland) at p<0.05.
MATERIALS AND METHODS

Reagents
Inhibitory activity of single phenolic acids.
Each single phenolic acid was tested, as described above, using sixteen solutions in the range of 0.29 mmol/L -2.00 mmol/L. A dose-response curve for each phenolic acid was plotted.
Inhibitory activity of combined phenolic acids. Seven phenolic acids (4-OH-PP, CA, CHA, GA, HGA, NDGA, RA, 15 μL each, 2 mmol/L) were combined and mixed with all reagents to determine anticholinesterase activities, as described above. Each sample was analyzed in four repeats.
Inhibitory activity of phenolic acids in pairs. Phenolic acids (4-OH-PP, CA, CHA, GA, HGA, NDGA and RA, 15 μL each, 2 mmol/L) were mixed in pairs with all reagents to determine anticholinesterase activities, as described above. . Each flavonoid was also tested singly. Anticholinesterase activities were studied as described above. HVA > SA (significant as well as non-significant differences, see Table 2 ). In the case of anti-BChE activity, the order of phenolic acids was (Tab. 3): NDGA > HGA > CHA > 4-OH-PP > RA > CA = GA > HVA = SA (significant as well as non-significant differences). HVA and SA, although exerting distinct activities, were the least efficient AChE inhibitors in this study (detailed results not shown) and were excluded from the subsequent parts of the study. For further stages, a phenolic acid concentration of 0.86 mmol/L was chosen.
RESULTS
Inhibiton
Inhibitory activity of combined phenolic acids. The antiAChE activity of all phenolic acids calculated from doseresponse curves as the sum of the inhibitory activities of individual compounds was 20.8 ± 1.8 μmol/L of eserine. However, the measured inhibitory activity was significantly (p<0.05) lower and amounted to only 2.9 ± 0.2 μmol/L of eserine. Similarly, the sum of anti-BChE activities of all phenolic acids singly was 16.9 ± 1.5 μmol/L of eserine and it was significantly (p<0.05) higher than the detected activity of the mixture of all phenolic acids (5.7 ± 0.4 μmol/L of eserine).
Inhibitory activity of phenolic acids in pairs.
The anti-AChE (Tab. 2) and anti-BChE activity (Tab. 3) of phenolic acids in pairs, each compound at 0.86 mmol/L, was, in most cases, lower than the sum of activities presented by two phenolic acids in separate solutions, although at a significance level of p>0.05. Only in the case of a few pairs (AChE: HGA + CHA, HGA + GA; BChE: NDGA + 4-OH-PP, NDGA + CA, NDGA + CHA, NDGA + GA, NDGA + RA) was the inhibitory activity significantly (p<0.05) lower than the sum of the activities presented by phenolic acids singly in solutions. Also, in the case of a few samples (AChE: GA + CHA, RA + CA, RA + CHA; BChE: GA + CA), the inhibitory activity of the solution containing two phenolic acids was equal to or higher than the sum of inhibitions exerted by the same two acids tested singly, although at a significance level of p>0.05 (Tab. 2, 3 ).
Inhibitory activity of phenolic acids matched with flavonoids. The anti-AChE and anti-BChE activity of phenolic acids coupled with flavonoids (Tab. 4, 5) , in most cases, was lower than the sum of activities of single compounds present in the solution, although at a significance level of p>0.05. Only in the case of two pairs (AChE: PHL + 4-OH-PP; BChE: PHL + NDGA) was the inhibitory activity significantly (p<0.05) lower than the sum of the activities presented by phenolic compounds singly in solutions. In selected samples (AChE: MYR + GA, KAE + GA, PEL + CHA, PEL + GA; BChE: KAE + HGA, KAE + GA), the inhibitory activity of the solution containing two phenolic compounds was higher than the sum of inhibitions exerted by the same compounds tested singly, although at a significance level of p>0.05 (Tab. 4, 5) .Finally, in the case of the pairs MYR + RA (AChE) and KAE + 4-OH-PP (BChE), the inhibitory activity was significantly (p<0.05) higher than the sum of the activities presented by phenolic compounds singly in solutions. * inhibitory activity lower than expected (p<0.05) † inhibitory activity lower than expected (p>0.05) ◊ inhibitory activity equal to the expected value or higher than expected value (p>0.05)
DISCUSSION
In the presented study, an attempt was made to study the interactions between cholinesterases and their inhibitorsphenolic acids and flavonoids. Phenolic compounds were chosen for testing, based on previous studies [2, 6, 18] . The results obtained in the current study confirm the in vitro anticholinesterase activity of these compounds. AChE and BChE share many structural similarities (50 -55% speciesdependent sequence similarity), and the active site of BChE (Ser198, His438 and Glu325) and oxyanion hole (Gly116, Gly117 and Ala199) are identical to those of AChE. However, differences in the inhibitory activity caused by individual phenolic compounds (Tab. 2-5) probably originate from some minor differences in the structures of both enzymes; for example, the active site of AChE is formed by fourteen aromatic amino acid residues, whereas in BChE, six or eight of them are replaced with aliphatic residues, depending on the origin of the enzyme [19] . Detailed comparisons of AChE and BChE have been presented in numerous review papers [20] . Phenolic compounds were efficient cholinesterase inhibitors singly in the solution, but combined phenolic acids, as well as phenolic acids coupled with flavonoids, were less efficient inhibitors than could have been expected (calculated) from the sum of activities exerted by both compounds. It should be strongly underlined that the lower activity of pairs of phenolic compounds in comparison to single compounds (Tab. 2-5) was not confirmed statistically in the case of most of the tested pairs (insignificant differences, p>0.05). Nevertheless, an explanation of this phenomenon could be sought in an analysis of the affinity of inhibitors to the enzyme molecules. The active site of AChE and BChE can be divided into several subsites: omega loop (Cys69 -Cys96), peripheral anionic subsite (Asp74, Tyr124, Ser125, Trp286, Tyr337, Tyr341), anionic subsite (Trp86, Tyr133, Glu202, Gly448, Ile451), oxyanion hole (Gly121, Gly122, Ala204), catalytic triad (Ser203, His447, Glu334), and acyl binding pocket (Trp236, Phe295, Phe297, Phe338) [21] . It is most likely that the phenolic acids and flavonoids studied in this work were simultaneously docking in different locations in the enzyme molecule, doubling the action of each inhibitor. Thus, the total inhibitory effect was lower than that expected from the results involving both phenolic compounds tested singly. Three-dimensional pharmacophore conformations of binding sites in AChE and BChE are essential for the non-covalent interaction of the enzyme with inhibitors, but the number of studies concerning the docking of phenolic compounds with AChE or BChE is limited. Therefore, the synergy/antagonism issues between individual phenolic compounds are, as yet, poorly elucidated. A synergistic effect of two inhibitors on a single target protein is possible in the case of two independent binding sites (e.g. active site and allosteric site), or if the active site is large enough to accommodate both inhibitors adjacent to one another.
It is known that AChE (BChE) may have various binding sites for ligands. QUE docked by hydroxyl groups in positions 5 and 7 in ring B to Tyr332, Trp430, Gly78, Tyr440, Trp82 and Ser198 [22] . In another study, QUE bound by several hydrogen bonds in the anionic subsite of AChE: O3 and O5 bound with the OH group of Tyr133 and O4 with the oxygen atom of Trp86. Moreover, the entire QUE molecule showed hydrophobic interactions with Ser125, His447 and Glu202 in the anionic subsite of AChE. The oxygen atoms of the phenyl side chain of QUE showed hydrogen bonding to the peripheral anionic subsite (O6 from QUE with O and OE1 atoms of the Tyr72 and Gln71, respectively, and O7 with the N atom of Asp74). QUE effectively bound to BChE by at least five hydrogen bonds: atoms O3 and O5 with atom OH of Tyr128 and atom O4 with the OG1 atom of Thr120, and atom O6 showed hydrogen bonds with the OD1 and N atoms of Asn83 and Asp70, respectively [23] . Alkenyl phenol and salicylic acid derivatives (+)-2-hydroxy-6-(10'hydroxypentadec-8'(E-enyl) benzoic acid, 2-hydroxy-6-(pentadec-10'(Z)-enyl)benzoic acid and 2-hydroxy-6-(10'(Z)-heptadecenyl)benzoic acid isolated from Knema laurina were effective inhibitors of AChE. All compounds were efficient AChE inhibitors due to the hydroxyl group binding to the carbonyl oxygen of Gly117 (hydrogen bonding). This, in turn, improved the positioning of the phenyl ring to involve a π-π stacking interaction with Trp84. The hydroxyl group in 2-hydroxy-6-(10'(Z)-heptadecenyl)benzoic acid was also involved in a short contact with Tyr130 [24] . Docking studies revealed that epigallocatechin gallate strongly bound to AChE via several hydrogen bonds to amino acids Glu202, Asn87, Asp74, Tyr124, His447, Tyr133 and Tyr337 [25] .
There is the possibility that some phenolic compounds may act as AChE (BChE) activators. Srividhya et al. [25] observed the activation of AChE by epigallocatechingallate in in silico and docking studies, as well as in in vivo studies involving Wistar rats. Caffeic acid was shown to increase AChE activity in the cerebral cortex, cerebellum, hypothalamus, whole blood, and also lymphocytes in the case of in vitro studies involving rats [26] . Moreover, caffeic acid increased AChE activity in vivo after co-administration with malathion to rats. The authors speculated that caffeic acid (or its derivate(s)) could lead to the activation of the catalytic site of AChE within the second site interaction [27] .
CONCLUSIONS
It can be stated that selected phenolic acids and flavonoids exhibit useful inhibitory activity towards AChE and BChE in model solutions. However, the results obtained in the presented study concerning synergism/no interaction between phenolic compounds, were not unequivocal. Therefore, as a next step, studies on the anticholinesterase activity of complex solutions (biological matrices), including docking studies, should be performed, as well as studies involving a wider range of phenolic compounds.
